| |
Wednesday, January 15, 2025 | 12pm ET / 9am PT Sort through the noise and hear from Washington Insiders. This session will offer key insights into the economic and political landscape, guiding your company on how best to prepare for and respond to potential changes in funding opportunities and compliance requirements. Register now.
|
|
Today’s Big NewsDec 19, 2024 |
|
Wednesday, January 15, 2025 | 11am ET / 8am PT Discover how next-gen Protein A resins and multi-column chromatography can help biomanufacturers optimize costs, enhance purification efficiency, and improve productivity. Learn practical strategies and explore real-world case studies showcasing advanced solutions for scalable, high-throughput processes. Register now.
|
|
| By Zoey Becker However, the combination of Merck's approved doravirine and investigational islatravir didn't prove superiority over Gilead's top-selling Biktarvy in one of the studies. |
|
|
|
By Fraiser Kansteiner Novartis confirmed Thursday that it’s closing down MorphoSys sites in Munich and Boston in a move that’s expected to result in around 330 layoffs. The company made the decision in November as it looks to “integrate all portfolio activities into Novartis." |
By Kevin Dunleavy An FDA advisory panel vote of 9-1 to recommend the approval of Mesoblast Limited’s graft versus host disease (GVHD) cell therapy was a cruel tease for the Australian company. More than four years later—and after two rejections from the agency—Mesoblast has finally gained an endorsement from the U.S. regulator for its first approved drug. |
By Nick Paul Taylor Vertex has reported a phase 2 win that dented confidence in its pain prospect suzetrigine. The trial linked the near-approval molecule to a significant improvement from baseline, but placebo performed similarly, triggering a 12% drop in Vertex’s share price in premarket trading. |
|
Antibody-based therapies have transformed the treatment of many diseases, with biologics remaining at the cutting-edge of R&D today. Access this insightful resource today to explore the traditional technologies used for finding antibody hits, and the latest innovations helping to overcome the top challenges with legacy methods. Download now.
|
|
By Conor Hale According to the clinical testing giant, its H5N1 test can be used to help check potential human exposure, as the virus has begun to spread through outbreaks at poultry farms and dairy herds across the country. |
By Andrea Park The ways in which pharmaceutical companies market their drugs directly to consumers in the U.S. could face quite the evolution in 2025—at least, if legislators and other government powers have anything to say about it. |
By Nick Paul Taylor Pharma’s reputation was 45% positive for the past two years. The latest survey put positive sentiment at 43%. After the whiplash changes of the COVID-19 era, things have settled down. Enter Donald Trump, a president-elect who fans and detractors alike agree has a propensity to try to shake things up. |
By Angus Liu Following in the footsteps of Pfizer, Roche and Takeda, another ALK inhibitor has made its belated entry into the U.S. The FDA nod comes four years after its initial approval in China. |
By Nick Paul Taylor Bristol Myers Squibb has turned to the source of Leqembi to further its push into Alzheimer’s disease, paying BioArctic $100 million upfront for global rights to two preclinical antibodies. |
By Nick Paul Taylor Launches from companies including Boehringer Ingelheim and Bristol Myers Squibb could drive sales of schizophrenia drugs up to $17 billion by 2031 despite generic erosion of incumbent products, according to GlobalData. |
By Conor Hale No hardware is being removed from use—instead, the company’s effort focuses on updating the instructions for the POLARx system, following higher-than-anticipated reports of damage to the esophagus, including seven injuries and four deaths. |
By Andrea Park Christmas seems to have come early for Klick Health, with a slew of new leaders arriving under the life sciences marketing agency’s metaphorical tree. |
Fierce podcastsDon’t miss an episode |
| | This week on "Podnosis," we explore how teaching kids social-emotional skills early can transform their lifelong wellbeing. |
|
|---|
|
|
|
The European orphan drug market presents a significant opportunity, with forecasts predicting substantial growth in the coming years. Early access programs (EAPs) have emerged as a critical strategy for successfully launching rare disease therapies in this complex and diverse market. Access this whitepaper to learn more.
|
|
| WhitepaperWe interviewed 14 R&D biopharma leaders on the critical success factors for building a Best Practice R&D organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperExplore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
| WhitepaperThe use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
| WhitepaperLearn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
